Total Payments
$597,351
2024 Payments
$27,640
Companies
11
Transactions
494
Medicare Patients
2,024
Medicare Billing
$410,610
Payment Breakdown by Category
Other$419,309 (70.2%)
Consulting$112,232 (18.8%)
Travel$49,250 (8.2%)
Food & Beverage$12,101 (2.0%)
Research$4,440 (0.7%)
Education$19.30 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $409,859 | 145 | 68.6% |
| Consulting Fee | $112,232 | 48 | 18.8% |
| Travel and Lodging | $49,250 | 110 | 8.2% |
| Food and Beverage | $12,101 | 174 | 2.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,250 | 3 | 0.9% |
| Unspecified | $4,440 | 5 | 0.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,200 | 5 | 0.7% |
| Education | $19.30 | 4 | 0.0% |
Payments by Type
General
$592,911
489 transactions
Research
$4,440
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $194,395 | 126 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $186,463 | 118 | $0 (2020) |
| Medtronic Vascular, Inc. | $70,921 | 115 | $0 (2020) |
| Lilly USA, LLC | $58,793 | 31 | $0 (2024) |
| Abbott Laboratories | $28,188 | 82 | $0 (2021) |
| Eli Lilly and Company | $19,800 | 8 | $0 (2023) |
| Amgen Inc. | $19,040 | 3 | $0 (2020) |
| GE Healthcare | $13,300 | 5 | $0 (2018) |
| Medtronic, Inc. | $3,675 | 3 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $2,750 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,640 | 7 | Boehringer Ingelheim Pharmaceuticals, Inc. ($27,340) |
| 2023 | $7,018 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,818) |
| 2022 | $27,622 | 16 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,472) |
| 2021 | $60,197 | 43 | Boehringer Ingelheim Pharmaceuticals, Inc. ($32,646) |
| 2020 | $83,247 | 43 | Lilly USA, LLC ($20,100) |
| 2019 | $126,129 | 112 | Novartis Pharmaceuticals Corporation ($40,132) |
| 2018 | $116,003 | 139 | Novartis Pharmaceuticals Corporation ($49,087) |
| 2017 | $149,495 | 129 | Novartis Pharmaceuticals Corporation ($90,907) |
All Payment Transactions
494 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: DIABETES | ||||||
| 08/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: DIABETES | ||||||
| 07/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $1,551.09 | General |
| Category: DIABETES | ||||||
| 07/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $1.00 | General |
| Category: DIABETES | ||||||
| 06/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $10,757.25 | General |
| Category: DIABETES | ||||||
| 06/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6,031.12 | General |
| Category: DIABETES | ||||||
| 05/09/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Diabetes | ||||||
| 11/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: DIABETES | ||||||
| 11/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: DIABETES | ||||||
| 07/18/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: DIABETES | ||||||
| 07/18/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 06/28/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $118.13 | General |
| Category: DIABETES | ||||||
| 10/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: DIABETES | ||||||
| 10/05/2022 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 10/02/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $690.23 | General |
| Category: DIABETES | ||||||
| 09/29/2022 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 09/22/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: DIABETES | ||||||
| 08/02/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: Diabetes | ||||||
| 06/03/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: DIABETES | ||||||
| 05/17/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 04/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: DIABETES | ||||||
| 04/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: DIABETES | ||||||
| 04/14/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: DIABETES | ||||||
| 04/14/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: DIABETES | ||||||
| 04/05/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $1,161.88 | General |
| Category: DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HVAD Smart 1.0 | Medtronic Vascular, Inc. | $1,575 | 1 |
| HVAD Smart 1.0 | Medtronic, Inc. | $975.00 | 1 |
| PSR-MCS | Medtronic Vascular, Inc. | $900.00 | 1 |
| DT PAS | Medtronic Vascular, Inc. | $540.00 | 1 |
| DT PAS | Medtronic, Inc. | $450.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 450 | 1,002 | $338,938 | $90,196 |
| 2022 | 12 | 569 | 1,175 | $456,533 | $120,068 |
| 2021 | 12 | 503 | 1,061 | $377,891 | $97,274 |
| 2020 | 12 | 502 | 1,192 | $414,313 | $103,071 |
Total Patients
2,024
Total Services
4,430
Medicare Billing
$410,610
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 145 | 165 | $71,610 | $24,449 | 34.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 36 | 130 | $88,140 | $23,409 | 26.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 176 | $38,192 | $11,841 | 31.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 115 | $35,765 | $11,701 | 32.7% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2023 | 34 | 144 | $40,032 | $5,131 | 12.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $15,023 | $4,155 | 27.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $12,983 | $3,113 | 24.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 36 | 39 | $8,424 | $2,525 | 30.0% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 13 | 13 | $11,791 | $1,509 | 12.8% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 11 | 150 | $9,750 | $1,224 | 12.6% |
| 93750 | Evaluation of lower heart chamber assist device | Office | 2023 | 21 | 26 | $7,228 | $1,140 | 15.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 54 | 196 | $132,888 | $37,221 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 137 | 161 | $69,874 | $23,572 | 33.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 69 | 217 | $67,487 | $18,862 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 86 | 198 | $43,014 | $12,010 | 27.9% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2022 | 40 | 206 | $57,268 | $7,362 | 12.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $25,046 | $7,083 | 28.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 20 | $12,348 | $3,390 | 27.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 48 | 55 | $11,880 | $3,304 | 27.8% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2022 | 17 | 17 | $15,419 | $2,016 | 13.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 23 | 24 | $6,000 | $1,842 | 30.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $5,823 | $1,396 | 24.0% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 12 | 14 | $4,760 | $1,337 | 28.1% |
| 93750 | Evaluation of lower heart chamber assist device | Office | 2022 | 14 | 17 | $4,726 | $672.96 | 14.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 36 | 130 | $88,140 | $25,192 | 28.6% |
About Dr. Jonathan Rich, M.D
Dr. Jonathan Rich, M.D is a Cardiovascular Disease healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467501064.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Rich, M.D has received a total of $597,351 in payments from pharmaceutical and medical device companies, with $27,640 received in 2024. These payments were reported across 494 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($409,859).
As a Medicare-enrolled provider, Rich has provided services to 2,024 Medicare beneficiaries, totaling 4,430 services with total Medicare billing of $410,610. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Advanced Heart Failure and Transplant Cardiology
- Location Chicago, IL
- Active Since 01/10/2007
- Last Updated 02/07/2020
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1467501064
Products in Payments
- JARDIANCE (Drug) $249,278
- ENTRESTO (Drug) $186,463
- HeartWare HVAD (Device) $61,459
- CardioMEMS HF System (Device) $17,167
- HeartMate 3 Left Ventricular Dev (Device) $7,557
- TRADJENTA (Drug) $5,000
- HeartMate 3 Left Ventricular Assist Device (Device) $2,333
- Claria MRI (Device) $770.00
- HeartMate (Device) $430.21
- Circulatory Support (Device) $401.35
- MitraClip System (Device) $140.51
- HeartMate II LVAS (Device) $108.38
- Proclaim Family of SCS IPGs (Device) $30.46
- 3F (Device) $28.33
- LifeVest (Device) $25.59
- CentriMag (Device) $20.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Chicago
Sandeep Nathan
Cardiovascular Disease — Payments: $950,057
Cardiovascular Disease $950,057
Michael Davidson
Cardiovascular Disease — Payments: $636,827
Cardiovascular Disease $636,827
Sanjiv Shah, Md, MD
Cardiovascular Disease — Payments: $448,175
Cardiovascular Disease $448,175
Boaz Avitall
Cardiovascular Disease — Payments: $337,061
Cardiovascular Disease $337,061
Daniel Fintel, Md, MD
Cardiovascular Disease — Payments: $254,863
Cardiovascular Disease $254,863
Adhir Shroff, M.d, M.D
Cardiovascular Disease — Payments: $231,800
Cardiovascular Disease $231,800